Bristol Myers Squibb

Summary

Bristol-Myers Squibb is the famous Corporate Investor, which was founded in 1887. The fund was located in North America if to be more exact in United States. The main department of described Corporate Investor is located in the New York.

The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Health Diagnostics, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Blade Therapeutics, PathAI, Personal Genome Diagnostics (PGD). Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Bristol-Myers Squibb, startups are often financed by Sprout Group, SR One, Refactor Capital. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Ysios Capital, Yonghua Capital. In the next rounds fund is usually obtained by Partners Investment, Symbiosis Group, Symbiosis.

The top amount of exits for fund were in 2014. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. This Bristol-Myers Squibb works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this Corporate Investor is 34 percentage points more often commits exit comparing to other organizations.

The fund was created by John Ripley Myers, William McLaren Bristol.